Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2022-10-31 Earnings Release
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Renalytix Reports Full Year Fiscal 2022 Results
Earnings Release Classification · 99% confidence The document explicitly states, 'Renalytix Reports Full Year Fiscal 2022 Results' and 'Investors are advised to read the results for the 12 months ended 30 June 2022, which have been filed with the U.S. Securities and Exchange Commission under Form 20-F concurrently with this results announcement.' Furthermore, the Chairman & CEO's statement begins, 'We are pleased to present our annual report for the twelve months ended 30 June 2022 for Renalytix plc.' Although it is an announcement (press release) detailing the results and mentioning an analyst call, the core subject is the release of the comprehensive annual financial performance data, which aligns best with the Annual Report category (10-K, or its equivalent for foreign private issuers like Form 20-F, which serves the same purpose). Since '10-K' is the designated code for the official yearly report covering full financial performance, it is the most appropriate classification, despite the document being structured as an Earnings Release (ER) or Report Publication Announcement (RPA) wrapper for the full annual filing. FY 2022
2022-10-31 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1930 characters) and contains the header 'RNS Number : 1692E'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange and explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, which is approved as a Primary Information Provider. This structure strongly indicates a general regulatory announcement or market notice rather than a specific financial report (like 10-K, IR, or ER). Since it is a direct regulatory announcement distributed via the RNS system and doesn't fit the specific categories like DIRS, DIV, or DLST, the most appropriate classification is the general Regulatory Filings category (RNS).
2022-10-26 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1913 characters) and contains the header 'RNS Number' and explicitly mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading mechanics, not a comprehensive financial report or a standard regulatory filing like a 10-K or IR. Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like DIV, DIRS, ER, etc.), the most appropriate classification is the general regulatory filing category, RNS.
2022-10-26 English
KidneyIntelX Medicare Update
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number and is dated October 25, 2022. It contains a section explicitly referencing 'Statements contained in this Report on Form 6-K (this "Report") regarding matters that are not historical facts...'. The presence of 'RNS Number' and the reference to 'Form 6-K' (a common SEC filing for foreign private issuers, often accompanying press releases) strongly suggests this is a regulatory announcement distributed via the London Stock Exchange's Regulatory News Service (RNS). The content is a press release announcing an update regarding Medicare payment for their product, KidneyIntelX. Since it is a formal announcement distributed via RNS and does not appear to be a full financial report (like 10-K or IR) or a specific type like a proxy statement or earnings release, the most appropriate classification is the general regulatory announcement category.
2022-10-25 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4073 characters) released via RNS (RNS Number: 7880D) on October 24, 2022. The core content states that Renalytix plc "will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022." It provides details for the subsequent conference call and webcast. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the future publication of results (like an Earnings Release or Annual Report) should be classified as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this specifically announces the *timing* of the financial results release and associated call, RPA is the most precise fit, as it signals the upcoming publication of the ER/10-K.
2022-10-24 English
Presentations accepted at ASN Kidney Week
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number and is dated October 17, 2022. It announces that four scientific presentations regarding the KidneyIntelX platform have been accepted at the upcoming American Society of Nephrology (ASN) Kidney Week. The text details the content of these presentations (cost-effectiveness, clinical utility, health inequity, biomarker analysis) and concludes with standard boilerplate information about the company, forward-looking statements, and the RNS distribution service disclaimer. This structure—a brief announcement detailing upcoming scientific/clinical data dissemination, often referencing an external event or publication—is characteristic of a general regulatory announcement rather than a full financial report (like 10-K or IR) or a specific management/governance filing. Since it is a general regulatory news release distributed via RNS and does not fit into the more specific categories (like ER, DIV, MANG, etc.), the most appropriate classification is the general regulatory filing fallback.
2022-10-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.